8-K: Sanara MedTech Invests in ChemoMouthpiece, Secures Exclusive Distribution Deal

Sanara MedTech has made a minority investment in ChemoMouthpiece and secured an exclusive U.S. distribution agreement for its oral cryotherapy device through a joint venture with InfuSystem.

Summary

• Sanara MedTech, through its subsidiary Sanara CMP, has purchased 100,674.72 common units in ChemoMouthpiece, LLC for $5.0 million, representing approximately 6.64% ownership.
• This investment is part of a broader agreement that includes an exclusive U.S. distribution deal for ChemoMouthpiece's oral cryotherapy device.
• The distribution will be handled by SI Healthcare Technologies, a joint venture between Sanara and InfuSystem.
• SI Technologies will be the sole distributor of ChemoMouthpiece's Standard Chemo Regiment Kits for a five-year term.
• Sanara has also borrowed an additional $15.5 million under its term loan agreement, with $5.0 million used for the ChemoMouthpiece investment and the remainder for acquisitions and working capital.
• The Chemo Mouthpiece device is a 510(k) cleared cryotherapy device designed to reduce the severity of chemotherapy-induced oral mucositis.
• The estimated market size for oral mucositis treatment exceeds $600 million annually in the U.S., with an estimated 500,000 to 1,000,000 patients affected.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with a strategic investment and distribution agreement, but the high interest rate on the loan and the inherent risks of the medical device industry temper the overall sentiment.

Positives

• The investment in ChemoMouthpiece provides Sanara with a stake in a company with a clinically validated product.
• The exclusive distribution agreement through SI Technologies leverages InfuSystem's existing sales network of approximately 3,000 cancer centers.
• The Chemo Mouthpiece device has the potential to improve patient quality of life and reduce healthcare costs associated with oral mucositis.
• The product aligns with Sanara's skincare strategy, which includes licensed collagen peptides for radiation dermatitis.
• The American Medical Association has issued a CPT code for cryotherapy procedures, which may facilitate reimbursement.

Negatives

• The company has taken on additional debt of $15.5 million at an interest rate of 13.25% per annum.
• The success of the distribution agreement depends on the ability of SI Technologies to effectively market and sell the Chemo Mouthpiece device.
• The company is subject to risks associated with market acceptance, competition, and regulatory approvals.

Risks

• The company faces risks related to the market acceptance of the Chemo Mouthpiece device.
• There are risks associated with the ability to penetrate oncology hospitals and clinics.
• The company is subject to competition and pricing pressures.
• There are uncertainties associated with the development and regulatory approval of new products.
• The company is subject to risks associated with integrating acquisitions.

Future Outlook

The company plans to market and distribute the Chemo Mouthpiece device through SI Technologies, leveraging InfuSystem's existing sales network. ChemoMouthpiece is planning to publish studies in the future reinforcing the efficacy of their product. Sanara intends to use the remaining proceeds from the loan for permitted acquisition opportunities and for general working capital and corporate purposes.

Management Comments

• Ron Nixon, Sanara's CEO, stated that the Chemo Mouthpiece device is a clinically validated product that can bring relief to oncology patients.
• Richard Dilorio, InfuSystem's CEO, believes the exclusive agreement will allow them to deliver efficacious products to patients.
• David Yoskowitz, ChemoMouthpiece's President and CEO, is confident that SI Technologies will successfully launch the Chemo Mouthpiece device.

Industry Context

This announcement reflects a growing trend in the medical device industry towards partnerships and strategic investments to expand market reach and address unmet medical needs. The focus on oral mucositis aligns with the increasing attention on supportive care for cancer patients.

Comparison to Industry Standards

• The investment and distribution agreement are similar to other strategic partnerships in the medical device industry, where companies collaborate to leverage each other's strengths.
• The focus on cryotherapy for oral mucositis is a growing area, with companies like Dignitana also offering similar solutions.
• The estimated market size of $600 million for oral mucositis treatment is consistent with industry reports on the prevalence and cost of this condition.
• The 13.25% interest rate on the loan is relatively high, which may be reflective of the risk profile of the company or the current lending environment.

Related Party Transactions

• The distribution agreement with SI Technologies, a joint venture between Sanara and InfuSystem, is a related party transaction.

Stakeholder Impact

• Shareholders may view the investment and distribution agreement positively, as it expands the company's product portfolio and market reach.
• Employees of Sanara and InfuSystem may benefit from the growth opportunities associated with the new product.
• Patients suffering from oral mucositis may benefit from the availability of the Chemo Mouthpiece device.
• Suppliers of ChemoMouthpiece may see increased demand for their products.

Next Steps

• SI Technologies will begin marketing and distributing the Chemo Mouthpiece device through InfuSystem's network.
• ChemoMouthpiece plans to publish studies reinforcing the efficacy of their product.
• Sanara will continue to explore acquisition opportunities and use the remaining loan proceeds for working capital.

Key Dates

Keywords

cryotherapy, oral mucositis, medical device, distribution agreement, minority investment, oncology, chemotherapy, Sanara MedTech, InfuSystem, SI Technologies